Autolus Therapeutics plc
AUTL
$1.51
-$0.06-3.82%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 10.12M | 10.09M | 10.50M | 10.50M | 1.70M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.12M | 10.09M | 10.50M | 10.50M | 1.70M |
| Cost of Revenue | 206.81M | 185.83M | 186.14M | 182.76M | 179.48M |
| Gross Profit | -196.69M | -175.74M | -175.64M | -172.26M | -177.78M |
| SG&A Expenses | 109.89M | 91.31M | 74.59M | 63.81M | 54.91M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 250.91M | 228.29M | 203.56M | 189.40M | 177.23M |
| Operating Income | -240.79M | -218.20M | -193.07M | -178.91M | -175.53M |
| Income Before Tax | -219.14M | -270.19M | -233.98M | -221.28M | -208.40M |
| Income Tax Expenses | 1.53M | 41.00K | -2.00K | -13.00K | -19.00K |
| Earnings from Continuing Operations | -220.66 | -270.23 | -233.98 | -221.26 | -208.38 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -220.66M | -270.23M | -233.98M | -221.26M | -208.38M |
| EBIT | -240.79M | -218.20M | -193.07M | -178.91M | -175.53M |
| EBITDA | -233.07M | -210.78M | -186.21M | -172.43M | -168.96M |
| EPS Basic | -0.87 | -1.21 | -1.16 | -1.21 | -1.20 |
| Normalized Basic EPS | -0.54 | -0.75 | -0.72 | -0.75 | -0.73 |
| EPS Diluted | -0.87 | -1.21 | -1.16 | -1.21 | -1.20 |
| Normalized Diluted EPS | -0.54 | -0.75 | -0.72 | -0.75 | -0.73 |
| Average Basic Shares Outstanding | 1.02B | 928.38M | 836.28M | 744.11M | 695.77M |
| Average Diluted Shares Outstanding | 1.02B | 928.38M | 836.28M | 744.11M | 695.77M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
